Immunogenicity and efficacy of pneumococcal vaccines
Knowledge building from the past and future regulatory directions
EventHumanVaccines
Slovak is available via eTranslation, the European Commission's machine translation service.
Translate to Slovak | Important information about machine translation
- The original event times are:
- pondelok, november 16, 2026 - 09:00 - 17:00 Amsterdam time (CET)
- utorok, november 17, 2026 - 09:00 - 17:00 Amsterdam time (CET)
Dátum
- , -, -
Umiestnenie
- OnlineEuropean Medicines Agency, Amsterdam, the Netherlands
Event summary
Streptococcus pneumoniae is a major cause of serious illness, particularly in young children, older adults, and immunocompromised individuals.
Although pneumococcal conjugate vaccines (PCVs) have substantially reduced disease burden and mortality worldwide, infants remain especially vulnerable and require early vaccination.
Constantly evolving epidemiology of pneumococcal disease continues to create challenges for vaccine development and implementation.
As manufacturers develop vaccines covering more serotypes to further reduce disease and antibiotic resistance, regulators and public health authorities continue to debate the most appropriate pathways for the development, evaluation, and approval of new pneumococcal vaccines.
The workshop aims to bring together researchers, vaccine developers, public health experts, and regulators to review the latest evidence, brainstorm on how to best optimise current vaccines and support the development of next-generation pneumococcal vaccines.